Actually Astellas is of course a little more than just a candidate, since on December 7, 2010 they took an equity participation in Cytori, with the first right to negotiate a deal on liver regeneration. Cytori explained this in a note as follows:

Such a partnership would likely revolve around what we refer to as our Version 2.0 Celution® and cell therapy technology (and what Astellas calls ‘regenerative drug technology’), which is the combination of cells with pharmaceutical agents to enhance certain properties or mechanisms of the cells. This could be accomplished by incubating the cells and pharma agent outside the body or injecting the cells in combination with a systemic delivery of the drug. In addition to their negotiating right, Astellas received the right to a non-voting seat on Cytori’s board of directors and a position on our scientific advisory board.

Some people close to the matter could report that this "regenerative DRUG technology" would be related to of course ADRCs AND the drug "PROGRAF". It is well-known that Prograf looses certain patent protection in the US in 2011, but its worth having a look on what it does.

Copyright Information

Copyright Fas Kuiters © 2016 All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites